Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia

被引:47
作者
Frydecka, I
Kosmaczewska, A
Bocko, D
Ciszak, L
Wolowiec, D
Kuliczkowski, K
Kochanowska, I
机构
[1] Polish Acad Sci, Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland
[2] Med Univ, Dept Haematol, PL-50367 Wroclaw, Poland
关键词
B-CLL; CD152 (CTLA-4); CD28; stimulation;
D O I
10.1038/sj.bjc.6601833
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the present study, we have examined the kinetics and magnitude of expression of the CD28 and CD152 molecules on unstimulated and anti-CD3 + rIL-2-stimulated peripheral blood CD4+ and CD8+ T cells in patients with chronic lymphocytic leukaemia (B-CLL) and controls. The mean percentages of both CD3+ /CD4+ /CD28+ and CD3+ /CD8+ /CD28+ cells were significantly lower in B-CLL than in controls before culture, decreased rapidly, reaching their lowest levels between 24 and 48 h, and returned to basal levels after 72 h of culture. In controls, the lowest proportions of CD3+ /CD4+ /CD28+ and CD3+ /CD8+ / CD28+ cells were found after 24 h and returned to prestimulation levels after 48 h of stimulation, We observed significantly higher proportions of unstimulated CD3+ /CD4+ /CD152 + and CD3+ /CD8+ /CD152+ cells in B-CLL patients than in controls. The highest percentages of CD3+ /CD4+ /CD152 + and CD3+ /CD8+ /CD152 + cells were observed in controls after 72 h, and in B-CLL patients after 24 h, and remained statistically higher after 48, 72 and 96 h of stimulation. CD152 molecule expression returned to prestimulation levels after 96 h of culture in controls, and after 120 h in B-CLL patients. The abnormal kinetics and levels of CD28 and CD152 expression on T cells in B-CLL may lead to a state of hyporesponsiveness or anergy and could be one of the mechanisms of immune deficiency in this disease. (C) 2004 Cancer Research UK.
引用
收藏
页码:2042 / 2048
页数:7
相关论文
共 33 条
[1]   SERUM LEVELS OF TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
ADAMI, F ;
GUARINI, A ;
PINI, M ;
SIVIERO, F ;
SANCETTA, R ;
MASSAIA, M ;
TRENTIN, L ;
FOA, R ;
SEMENZATO, G .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (09) :1259-1263
[2]  
AZUMA M, 1993, J IMMUNOL, V150, P1147
[3]  
Bartik MM, 1998, SEMIN ONCOL, V25, P27
[4]  
Blair PJ, 1998, J IMMUNOL, V160, P12
[5]  
Bocko D, 2002, ARCH IMMUNOL THER EX, V50, P169
[6]  
Bojarska-Junak A, 2002, HAEMATOLOGICA, V87, P490
[7]   Down-regulation of CD28 expression by TNF-α [J].
Bryl, E ;
Vallejo, AN ;
Weyand, CM ;
Goronzy, JJ .
JOURNAL OF IMMUNOLOGY, 2001, 167 (06) :3231-3238
[8]   CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression [J].
Carreno, BM ;
Bennett, F ;
Chau, TA ;
Ling, V ;
Luxenberg, D ;
Jussif, J ;
Baroja, ML ;
Madrenas, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1352-1356
[9]   Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells [J].
Chen, WJ ;
Jin, WW ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (10) :1849-1857
[10]   EXPANSION OF T-CELLS EXPRESSING LOW CD4 OR CD8 LEVELS IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA - CORRELATION WITH DISEASE STATUS AND NEOPLASTIC PHENOTYPE [J].
DIANZANI, U ;
OMEDE, P ;
MARMONT, F ;
DIFRANCO, D ;
FUSARO, A ;
BRAGARDO, M ;
REDOGLIA, V ;
GIARETTA, F ;
MAIRONE, L ;
BOCCADORO, M ;
RESEGOTTI, L ;
PILERI, A .
BLOOD, 1994, 83 (08) :2198-2205